Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. The Optimal First-line Therapy For Extensive-stage Small-cell Lung Cancer Based On Liver Metastasis Status: A Network Meta-analysis And Systematic Review.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. The Optimal First-line Therapy For Extensive-stage Small-cell Lung Cancer Based On Liver Metastasis Status: A Network Meta-analysis And Systematic Review.

Related Experiment Video

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.2K

The Optimal First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer Based on Liver Metastasis Status: A Network Meta-Analysis and Systematic Review.

Shu-Ling Zhang1,2,3, Jing Yu1,2, Yuan Tian1,2

  • 1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.

Cancer Medicine
|October 3, 2024

View abstract on PubMed

Summary
This summary is machine-generated.
Keywords:
immunotherapyliver metastasesmeta‐analysissmall‐cell lung cancer

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K
Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis
04:22

Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis

Published on: March 3, 2023

366

Related Experiment Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.2K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K
Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis
04:22

Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis

Published on: March 3, 2023

366

Chemo-immunotherapy (CIT) improves survival in extensive-stage small-cell lung cancer (ES-SCLC) patients, with or without liver metastases (LM). For LM patients, anti-PD-1 plus chemotherapy is optimal; for non-LM patients, anti-angiogenesis, anti-PD-L1, and chemotherapy offer the best outcomes.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Extensive-stage small-cell lung cancer (ES-SCLC) presents a significant therapeutic challenge.
  • First-line treatment strategies are evolving with the advent of immune checkpoint inhibitors.
  • The presence of liver metastases (LM) may influence treatment efficacy in ES-SCLC.

Purpose of the Study:

  • To compare the effectiveness of first-line programmed cell death (ligand) [PD-(L)1] blockade-based regimens in ES-SCLC patients.
  • To evaluate treatment efficacy in ES-SCLC patients with and without liver metastases (LM).
  • To identify optimal first-line treatment strategies for ES-SCLC based on PD-(L)1 blockade.

Main Methods:

  • A network meta-analysis of randomized controlled trials (RCTs) was conducted.
  • Studies compared chemo-immunotherapy (CIT) against chemotherapy (CT) in ES-SCLC patients, stratified by LM status.
  • Overall survival (OS) and progression-free survival (PFS) were assessed using hazard ratios (HRs) and 95% confidence intervals (CIs).

    • Main Results:

    • Seven RCTs involving 3658 ES-SCLC patients were analyzed.
    • In patients with LM, anti-PD-1 + CT (HR, 0.67) and anti-PD-L1 + CT + anti-angiogenesis (HR, 0.84) significantly improved OS versus CT alone.
    • The anti-PD-1 + CT regimen showed the highest cumulative probability (91.6%) for OS improvement in LM patients. For non-LM patients, anti-angiogenesis + anti-PD-L1 + CT ranked highest (95.5% cumulative probability for OS).

    Conclusions:

    • Chemo-immunotherapy (CIT) demonstrates efficacy in ES-SCLC patients irrespective of liver metastasis (LM) status.
    • For ES-SCLC patients with LM, combining PD-1 blockade with chemotherapy represents the optimal first-line strategy.
    • For ES-SCLC patients without LM, the combination of anti-angiogenesis, PD-L1 blockade, and chemotherapy is the most beneficial regimen.